about
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.GAS6 expression identifies high-risk adult AML patients: potential implications for therapyPrognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8.Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemiaResidual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid LeukemiamiR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemiaThe MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemiaBortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia.Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene scoreSPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.Extracellular crystals in plasma cell myelomaIn rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline.Salvage therapy in Hodgkin's lymphoma.A medical experience that taught me about humanism in medicine.Novel mHealth App to Deliver Geriatric Assessment-Driven Interventions for Older Adults With Cancer: Pilot Feasibility and Usability StudyTCR antigen-induced cell death occurs from a late G1 phase cell cycle check pointIndex case of acute myeloid leukemia in a family harboring a novel CEBPA germ line mutation
P50
Q27851839-896B236E-7782-4652-AE78-5BFA30546964Q33717707-BB6D776C-717D-4A61-84B1-D29511B21B5DQ34119417-D33E2530-F8E6-4291-89DF-F9EFE820583CQ35152173-2DE6920E-F94B-4C6E-BE05-8E661B6E4A63Q35692708-58FFDAE4-14DF-4F95-B092-3E7256DD269DQ36100455-2AEDB6F5-C597-4289-B8FA-99D8CBF8B2D5Q36591431-0C4B262B-9A22-478B-99E5-6490F7037340Q37326210-1EF5689C-775B-4618-9222-0BA18614442AQ37474559-D8EAED96-A054-465B-A1A1-D81812DBA6B5Q37570427-E83377C0-214A-4F33-94B0-6E9F4818F041Q37679943-F0FCB1A3-770D-4CCD-8C14-6CFDD19F4836Q42720804-B3278097-3833-4FBD-B5BD-8195719370AFQ43065871-823ADEF3-F8ED-4FBB-BB5B-FB32D9A0063EQ47641019-E497A527-F714-4C20-A565-A700CA83D09EQ53273353-C7DBCBC5-89CB-434B-A641-9A844862892EQ58105114-7BC10096-8DDF-434D-A4A3-72DAD73E256EQ74171887-934E8FFB-1D67-42A9-869F-7081ACCE1E34Q89777971-19BC5A08-3329-4E49-B350-6F0C55838259
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jason Mendler
@ast
Jason Mendler
@en
Jason Mendler
@es
Jason Mendler
@nl
Jason Mendler
@sl
type
label
Jason Mendler
@ast
Jason Mendler
@en
Jason Mendler
@es
Jason Mendler
@nl
Jason Mendler
@sl
prefLabel
Jason Mendler
@ast
Jason Mendler
@en
Jason Mendler
@es
Jason Mendler
@nl
Jason Mendler
@sl
P106
P1153
9134050900
P21
P31
P496
0000-0001-5605-5324